Join Transform 2021 this July 12-16. Register for the AI event of the year.

Gene Security Network, provider of a test used to screen chromosomes in in-vitro fertilization processes, has brought in $6 million in second-round funding to grow its sales and marketing operations. The investment, paired with grants received from the National Institutes of Health, will give the Redwood City, Calif. company a two-year runway, it says.

The test, already being sold, detects chromosomal abnormalities that might lead to Down Syndrome and other conditions. It’s currently being offered at select in-vitro fertilization clinics across the country.

Claremont Creek Ventures led the round, which also included Sequoia Capital and Alafi Capital. Gene Security Network has raised $10 million to date.


VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
  • up-to-date information on the subjects of interest to you
  • our newsletters
  • gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
  • networking features, and more
Become a member